Associate Professor Shaun Fleming said the listing of Blincyto meant patients could avoid the potentially fatal side effects of chemotherapy. “Typically, patients with ALL are being treated with ...

Amgen’s Blincyto has been granted a full European licence in a form of blood cancer following data showing the drug almost doubled overall survival time compared with standard therapy.

After hours: March 11 at 4:08:09 PM EDT Loading Chart for PUMP ...